Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kintara Therapeutics Inc
(NQ:
KTRA
)
0.2278
-0.0022 (-0.96%)
Streaming Delayed Price
Updated: 12:40 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kintara Therapeutics Inc
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
August 19, 2024
Via
ACCESSWIRE
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
July 08, 2024
Via
ACCESSWIRE
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
July 01, 2024
Via
ACCESSWIRE
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
June 03, 2024
Via
ACCESSWIRE
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA
April 05, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
KTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to Shareholders
April 03, 2024
From
Halper Sadeh LLC
Via
Business Wire
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
April 03, 2024
Via
ACCESSWIRE
Is Kintara Therapeutics A Hidden Gem?
December 30, 2022
Kintara Therapeutics' earnings are in the red but impressive FDA approvals could satisfy an extreme upside potential to bring them solvent by next year.
Via
MarketBeat
Exposures
Product Safety
Kintara Therapeutics (NASDAQ: KTRA) Granted Orphan Drug Status for VAL-083 and the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
December 15, 2022
Kintara Therapeutics, Inc. (NASDAQ: KTRA) is engaged as a biopharmaceutical company, which is focused on the research and development of
Via
Spotlight Growth
Exposures
Product Safety
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
December 01, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug...
Via
FinancialNewsMedia
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.